Immunotherapy in genitourinary malignancies
Abstract Treatment of cancer patients involves a multidisciplinary approach including surgery, radiotherapy, and chemotherapy. Traditionally, patients with metastatic disease are treated with combination chemotherapies or targeted agents. These cytotoxic agents have good response rates and achieve p...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-04-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13045-017-0457-4 |
| _version_ | 1819210214170165248 |
|---|---|
| author | Kathan Mehta Keyur Patel Rahul A. Parikh |
| author_facet | Kathan Mehta Keyur Patel Rahul A. Parikh |
| author_sort | Kathan Mehta |
| collection | DOAJ |
| description | Abstract Treatment of cancer patients involves a multidisciplinary approach including surgery, radiotherapy, and chemotherapy. Traditionally, patients with metastatic disease are treated with combination chemotherapies or targeted agents. These cytotoxic agents have good response rates and achieve palliation; however, complete responses are rarely seen. The field of cancer immunology has made rapid advances in the past 20 years. Recently, a number of agents and vaccines, which modulate the immune system to allow it to detect and target cancer cells, are being developed. The benefit of these agents is twofold, it enhances the ability the body’s own immune system to fight cancer, thus has a lower incidence of side effects compared to conventional cytotoxic chemotherapy. Secondly, a small but substantial number of patients with metastatic disease are cured by immunotherapy or achieve durable responses lasting for a number of years. In this article, we review the FDA-approved immunotherapy agents in the field of genitourinary malignancies. We also summarize new immunotherapy agents being evaluated in clinical studies either as single agents or as a combination. |
| first_indexed | 2024-12-23T06:07:37Z |
| format | Article |
| id | doaj.art-0975a6b58a6441bd981d79a35e27ece9 |
| institution | Directory Open Access Journal |
| issn | 1756-8722 |
| language | English |
| last_indexed | 2024-12-23T06:07:37Z |
| publishDate | 2017-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj.art-0975a6b58a6441bd981d79a35e27ece92022-12-21T17:57:32ZengBMCJournal of Hematology & Oncology1756-87222017-04-0110111410.1186/s13045-017-0457-4Immunotherapy in genitourinary malignanciesKathan Mehta0Keyur Patel1Rahul A. Parikh2Department of Medicine, University of Pittsburgh Medical CenterDepartment of Medicine, University of Pittsburgh Medical CenterDepartment of Medicine, University of Pittsburgh Medical CenterAbstract Treatment of cancer patients involves a multidisciplinary approach including surgery, radiotherapy, and chemotherapy. Traditionally, patients with metastatic disease are treated with combination chemotherapies or targeted agents. These cytotoxic agents have good response rates and achieve palliation; however, complete responses are rarely seen. The field of cancer immunology has made rapid advances in the past 20 years. Recently, a number of agents and vaccines, which modulate the immune system to allow it to detect and target cancer cells, are being developed. The benefit of these agents is twofold, it enhances the ability the body’s own immune system to fight cancer, thus has a lower incidence of side effects compared to conventional cytotoxic chemotherapy. Secondly, a small but substantial number of patients with metastatic disease are cured by immunotherapy or achieve durable responses lasting for a number of years. In this article, we review the FDA-approved immunotherapy agents in the field of genitourinary malignancies. We also summarize new immunotherapy agents being evaluated in clinical studies either as single agents or as a combination.http://link.springer.com/article/10.1186/s13045-017-0457-4ImmunotherapyGenitourinary malignancyCheckpoint inhibitorPD-1PD-L1CTLA-4 |
| spellingShingle | Kathan Mehta Keyur Patel Rahul A. Parikh Immunotherapy in genitourinary malignancies Journal of Hematology & Oncology Immunotherapy Genitourinary malignancy Checkpoint inhibitor PD-1 PD-L1 CTLA-4 |
| title | Immunotherapy in genitourinary malignancies |
| title_full | Immunotherapy in genitourinary malignancies |
| title_fullStr | Immunotherapy in genitourinary malignancies |
| title_full_unstemmed | Immunotherapy in genitourinary malignancies |
| title_short | Immunotherapy in genitourinary malignancies |
| title_sort | immunotherapy in genitourinary malignancies |
| topic | Immunotherapy Genitourinary malignancy Checkpoint inhibitor PD-1 PD-L1 CTLA-4 |
| url | http://link.springer.com/article/10.1186/s13045-017-0457-4 |
| work_keys_str_mv | AT kathanmehta immunotherapyingenitourinarymalignancies AT keyurpatel immunotherapyingenitourinarymalignancies AT rahulaparikh immunotherapyingenitourinarymalignancies |